PCRX — Pacira BioSciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1396814 ·
Last close
$23.21
Market Cap
$913.27M
52W High
$27.13
52W Low
$21.16
ADV30
556,226
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 177,376,000 | 140,963,000 | 4,625,000 | 2,916,000 | 1,208,534,000 | 144,306,000 | 554,641,000 |
| Dec 2025 | 196,873,000 | 156,574,000 | -10,921,000 | 1,637,000 | 1,264,917,000 | 158,545,000 | 571,806,000 |
| Sep 2025 | 179,516,000 | 145,238,000 | 13,153,000 | 5,432,000 | 1,297,577,000 | 147,589,000 | 570,363,000 |
| Jun 2025 | 181,099,000 | 140,233,000 | 9,133,000 | -4,847,000 | 1,537,262,000 | 300,484,000 | 779,495,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$142,215,000
Investing CF
$144,551,000
Financing CF
$-426,031,000
CapEx
$-9,509,000
Dividends Paid
—
Buybacks
$-198,373,000
EPS Diluted TTM
$0.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-196,406,000
Inventory
$150,370,000
Receivables
$125,635,000
ST Investments
$57,874,000
EBIT TTM
$27,215,000
Pretax Income TTM
$13,166,000
Interest Exp TTM
$14,049,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$734,864,000
EBITDA
$121,288,000
Free Cash Flow
$98,615,624
Enterprise Value
$1,108,492,544
Total Cash
$202,180,000
Total Debt
$411,179,008
Shares Out
39,347,924
Trailing EPS
$0.13
Book Value
$16.63
ROE
0.7%
ROA
1.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 726,411,000 | 19,191,000 | 7,034,000 | 1,264,917,000 | 571,806,000 | — | 151,994,000 |
| Dec 2024 | 700,966,000 | 89,872,000 | -99,560,000 | 1,553,516,000 | 775,168,000 | — | 189,389,000 |
| Dec 2023 | 674,978,000 | 87,675,000 | 41,955,000 | 1,574,386,000 | 704,256,000 | — | 154,649,000 |
| Dec 2022 | 666,823,000 | 60,024,000 | 15,909,000 | 1,681,200,000 | 906,190,000 | — | 145,274,000 |
TTM Snapshot
Revenues TTM
$637,137,000
NetIncome TTM
$46,711,000
OpCashFlow TTM
$0
Assets (Latest)
$1,553,516,000
Forward EPS
$3.64
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $23.21 · call volume: 101 · put volume: 21Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | $912.78M | $10.45 | — |
| JBIO | Jade Biosciences, Inc. | $926.29M | $15.22 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $934.44M | $9.41 | — |
| PHAR | Pharming Group N.V. | $889.17M | $12.59 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $888.91M | $20.16 | — |
News headlines (Yahoo Finance, 1h cache)
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
2026-06-09 21:53 · Yahoo
Egan-Jones Recommends Pacira Shareholders Support All Management Nominees
2026-06-05 21:41 · Yahoo
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
2026-06-04 20:20 · Yahoo
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
2026-06-01 20:50 · Yahoo
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
2026-05-28 20:20 · Yahoo
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION
2026-05-28 13:18 · Yahoo
Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details
2026-05-27 21:18 · Yahoo
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
2026-05-27 20:20 · Yahoo
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
2026-05-27 12:00 · Yahoo
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
2026-05-26 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.